Evidence map›Paper›PMID 34579578›Full record

ArticlemBio2021

Preclinical Evaluation of Recombinant Microbial Glycoside Hydrolases in the Prevention of Experimental Invasive Aspergillosis.

Hanna Ostapska, Deepa Raju, Melanie Lehoux, Ira Lacdao, Stephanie Gilbert, Piyanka Sivarajah, Natalie C Bamford, Perrin Baker, Thi Tuyet Mai Nguyen, Caitlin A Zacharias and 3 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Identification of Compounds PreventingInternational journal of molecular sciences · 2023
    Article
  8. Review
  9. Article
  10. Co-Operative Biofilm Interactions betweenJournal of fungi (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Hanna Ostapska *Department of Microbiology and Immunology, McGill Universitygrid.14709.3b, Montreal, Canada.
Deepa Raju *Program in Molecular Medicine, Research Institute, The Hospital for Sick Childrengrid.42327.30, Toronto, Canada.
Melanie LehouxDepartment of Microbiology and Immunology, McGill Universitygrid.14709.3b, Montreal, Canada.
Ira LacdaoInfectious Disease and Immunity in Global Health Program, McGill Universitygrid.14709.3b Health Centre, Montreal, Canada.
Stephanie GilbertProgram in Molecular Medicine, Research Institute, The Hospital for Sick Childrengrid.42327.30, Toronto, Canada.
Piyanka SivarajahProgram in Molecular Medicine, Research Institute, The Hospital for Sick Childrengrid.42327.30, Toronto, Canada.
Natalie C BamfordProgram in Molecular Medicine, Research Institute, The Hospital for Sick Childrengrid.42327.30, Toronto, Canada.
Perrin BakerProgram in Molecular Medicine, Research Institute, The Hospital for Sick Childrengrid.42327.30, Toronto, Canada.
Thi Tuyet Mai NguyenInfectious Disease and Immunity in Global Health Program, McGill Universitygrid.14709.3b Health Centre, Montreal, Canada.
Caitlin A ZachariasDepartment of Microbiology and Immunology, McGill Universitygrid.14709.3b, Montreal, Canada.
Fabrice N GravelatDepartment of Microbiology and Immunology, McGill Universitygrid.14709.3b, Montreal, Canada.
P Lynne HowellProgram in Molecular Medicine, Research Institute, The Hospital for Sick Childrengrid.42327.30, Toronto, Canada.ORCID 0000-0002-2776-062X
Donald C SheppardDepartment of Microbiology and Immunology, McGill Universitygrid.14709.3b, Montreal, Canada.
McGill University Health Centre · CAHospital for Sick Children · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aspergillus fumigatus is a ubiquitous mold that can cause invasive pulmonary infections in immunocompromised patients. Within the lung, A. fumigatus forms biofilms that can enhance resistance to antifungals and immune defenses. Aspergillus biofilm formation requires the production of a cationic matrix exopolysaccharide, galactosaminogalactan (GAG). In this study, recombinant glycoside hydrolases (GH)s that degrade GAG were evaluated as antifungal agents in a mouse model of invasive aspergillosis. Intratracheal GH administration was well tolerated by mice. Pharmacokinetic analysis revealed that although GHs have short half-lives, GH prophylaxis resulted in reduced fungal burden in leukopenic mice and improved survival in neutropenic mice, possibly through augmenting pulmonary neutrophil recruitment. Combining GH prophylaxis with posaconazole treatment resulted in a greater reduction in fungal burden than either agent alone. This study lays the foundation for further exploration of GH therapy in invasive fungal infections.

Indexed as

AnimalsAntifungal AgentsAspergillus fumigatusBiofilmsDisease Models, AnimalDrug Evaluation, PreclinicalFemaleGlycoside HydrolasesInvasive Pulmonary AspergillosisMiceMice, Inbred BALB CNeutropeniaRecombinant ProteinsVirulenceAntifungal AgentsGlycoside HydrolasesRecombinant Proteinsantifungal agentsantimicrobial combinationsAspergillus fumigatusbiofilmexopolysaccharidefilamentous fungigalactosaminogalactan (GAG)glycoside hydrolase (GH)pulmonary aspergillosis

Identifiers

PMID34579578
PMCPMC8546845
OpenAlexW3202541944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.